This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.

Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Products
  • Therapy Areas
  • Resources
  • Events & Webinars
  • Learning Zone
  • Podcasts
Resources

NUBEQA® (darolutamide) Resources

NUBEQA® (darolutamide)
nmCRPC case study

nmCRPC case study

Download Here
mHSPC case study

mHSPC case study

Download Here
mHSPC checklist

mHSPC checklist

Download Here
nmCRPC checklist

nmCRPC checklist

Download Here
Patient leaflet

Patient leaflet

Download Here
Living with Prostate cancer Nubeqa Booklet

Living with Prostate cancer Nubeqa Booklet

Download Here
NUBEQA Prescribing Information
NUBEQA
NUBEQA® (darolutamide)
Learn more about local and international guidelines
PP-NUB-GB-2749, October 2025
NUBEQA
NUBEQA® (darolutamide)
About NUBEQA
PP-NUB-GB-2950, March 2026
NUBEQA® (darolutamide) Drug-Drug Interactions Learning Guide - CC
NUBEQA® (darolutamide) Drug-Drug Interactions Learning Guide
PP-NUB-GB-2129, March 2025

PP-NUB-GB-2863 | February 2026